ArticleBreast cancer research : BCR2026
Tumor cell Jagged-1 promotes regional lymphatic metastasis and predicts recurrence in node-positive breast cancer.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundLymph node metastasis marks a clinically and biologically important transition in breast cancer, reflecting more aggressive disease and increased risk of recurrence. Expression of the Notch ligand JAG1 is linked to poor breast cancer outcomes, but its role in lymphatic dissemination is unclear.
methodsTumor microarray analysis with multiplex staining was performed on synchronous breast and lymph node metastases from node-positive patients to quantify JAG1 expression and correlate findings with clinical outcomes. Orthotopic implantation of human and murine breast cancer cells was used to assess the impact of JAG1 expression on lymphovascular invasion and lymph node metastasis in vivo. The contribution of VEGFR3 signaling to JAG1-mediated lymphatic dissemination was evaluated using a soluble VEGFR3 antagonist. The cell-specific response of lymphatic endothelial cells to JAG1 was assessed by transendothelial migration assays, barrier examination, and sequencing.
resultsMammary tumor cells expressing JAG1 demonstrated increased lymphovascular and lymph node metastasis in mouse models. Inhibition with a soluble VEGFR3 antagonist attenuated JAG1-dependent lymph node metastasis. Exposure to JAG1 disrupted lymphatic endothelial barrier integrity, promoted tumor cell migration across cultured endothelium, and induced pro-inflammatory and pro-adhesion changes in lymphatic endothelial cells. Tumor microarray analyses revealed enrichment of JAG1 in metastatic tumor cells within lymph nodes relative to matched primary tumors. High JAG1 expression in lymph node metastases was significantly associated with increased risk of recurrence.
conclusionsThese findings support a role for tumor cell JAG1 promoting lymphatic dissemination and lymph node metastasis in breast cancer through effects on lymphatic endothelial signaling and barrier function. Enrichment of JAG1 in lymph node metastases and its association with recurrence further support its potential utility as a prognostic biomarker and therapeutic target in node-positive breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.